Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 2206 AL 2220

Spirituality and Spiritual Distress in Parkinson's Disease Caregivers: A Scoping Review

Seshadri S, Sugiura K, Mirham M, Aamodt WW, Kluger BM.

J Relig Health. 2023 Dec;62(6):4222-4243. doi: 10.1007/s10943-023-01913-5. Epub 2023 Sep 13.

Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease

Tesson C, Bouchetara MS, Ferrien M, Lesage S, Brice A.

Mov Disord. 2023 Sep;38(9):1756-1757. doi: 10.1002/mds.29533. Epub 2023 Jul 11.

Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson's Disease

Kakoty V, Kalarikkal Chandran S, Gulati M, Goh BH, Dua K, Kumar Singh S.

Drug Discov Today. 2023 Jun;28(6):103582. doi: 10.1016/j.drudis.2023.103582. Epub 2023 Apr 5.

Mendelian randomization analysis does not reveal a causal influence of mental diseases on osteoporosis

Tang F, Wang S, Zhao H, Xia D, Dong X.

Front Endocrinol (Lausanne). 2023 Apr 20;14:1125427. doi: 10.3389/fendo.2023.1125427. eCollection 2023.

Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PINK1-deficient Human Dopamine Neurons

Wang H, Chen R, Xiao L, Kumar M, Acevedo-Cintrón J, Siuda J, Koziorowski D, Wszolek ZK, Dawson VL, Dawson TM.

bioRxiv [Preprint]. 2023 Jun 26:2023.06.23.546087. doi: 10.1101/2023.06.23.546087.

A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population

Han C, Zhao ZZ, Chan P, Li F, Chi CL, Zhang X, Zhao Y, Chen J, Ma JH.

Vaccine. 2023 Oct 13;41(43):6483-6494. doi: 10.1016/j.vaccine.2023.09.002. Epub 2023 Sep 17.

Alterations in neurotransmitter co-release in Parkinson's disease

Barcomb K, Ford CP.

Exp Neurol. 2023 Dec;370:114562. doi: 10.1016/j.expneurol.2023.114562. Epub 2023 Oct 5.

Central and peripheral innate and adaptive immunity in Parkinson's disease

Harms AS, Yang YT, Tansey MG.

Sci Transl Med. 2023 Nov 8;15(721):eadk3225. doi: 10.1126/scitranslmed.adk3225. Epub 2023 Nov 8.

Could exercise hormone irisin be a therapeutic agent against Parkinson's and other neurodegenerative diseases?

Avgerinos KI, Liu J, Dalamaga M.

Metabol Open. 2023 Jan 31;17:100233. doi: 10.1016/j.metop.2023.100233. eCollection 2023 Mar.

Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study

Di Fonzo A, Percetti M, Monfrini E, Palmieri I, Albanese A, Avenali M, Bartoletti-Stella A, Blandini F, Brescia G, Calandra-Buonaura G, Campopiano R, Capellari S, Colangelo I, Comi GP, Cuconato G, Ferese R, Galandra C, Gambardella S, Garavaglia B, Gaudio A, Giardina E, Invernizzi F, Mandich P, Mineri R, Panteghini C, Reale C, Trevisan L, Zampatti S, Cortelli P, Valente EM; PARKNET study group.

Mov Disord. 2023 Dec;38(12):2241-2248. doi: 10.1002/mds.29617. Epub 2023 Sep 26.

Neuroimaging uncovers distinct relationships of glymphatic dysfunction and motor symptoms in Parkinson's disease

Qin Y, He R, Chen J, Zhou X, Zhou X, Liu Z, Xu Q, Guo JF, Yan XX, Jiang N, Liao W, Taoka T, Wang D, Tang B.

J Neurol. 2023 May;270(5):2649-2658. doi: 10.1007/s00415-023-11594-5. Epub 2023 Mar 1.

Editorial: Brain dopaminergic mechanisms

Yang B, Romanov RA, Xu J, Mothet JP.

Front Synaptic Neurosci. 2023 Sep 27;15:1292511. doi: 10.3389/fnsyn.2023.1292511. eCollection 2023.

The role of exosomes in the diagnosis of Parkinson's disease

Shi Q, Kang W, Liu Z, Zhu X.

Heliyon. 2023 Oct 16;9(10):e20595. doi: 10.1016/j.heliyon.2023.e20595. eCollection 2023 Oct.

Meta-Analysis of the Mechanisms Underlying COVID-19 Modulation of Parkinson's Disease

Zhang J, Bishir M, Barbhuiya S, Chang SL.

Int J Mol Sci. 2023 Aug 31;24(17):13554. doi: 10.3390/ijms241713554.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias